Melanoma cell lysosome secretory burst neutralizes the CTL-mediated cytotoxicity at the lytic synapse

Nature Communications

Volumn 7, Issue , 2016, Pages

  Khazen, Roxana ^a,b,c   Müller, Sabina ^a,b,c   Gaudenzio, Nicolas ^a,b,c,e   Espinosa, Eric ^a,b,c   Puissegur, Marie Pierre ^a,b,c   Valitutti, Salvatore ^a,b,c,d  

^a INSERM   (France)

^b CNRS   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d Institut Universitaire du Cancer de Toulouse   (France)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN; GRANZYME B; PERFORIN; SHORT HAIRPIN RNA; SYNAPTOSOMAL ASSOCIATED PROTEIN 23; QB SNARE PROTEIN; QC SNARE PROTEIN; SNAP23 PROTEIN, HUMAN;

CELLS AND CELL COMPONENTS; CYTOPLASM; DEGRADATION; ENZYME ACTIVITY; PH; SECRETION; TOXICITY; TUMOR;

ARTICLE; CELL FUNCTION; CELL MIGRATION; CELLULAR SECRETION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENDOSOME; EXOCYTOSIS; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOLOGICAL SYNAPSE; IMMUNOSURVEILLANCE; LYSOSOME; MELANOMA; MELANOMA CELL; PH; PROTEIN DEGRADATION; PROTEIN EXPRESSION; CD8+ T LYMPHOCYTE; CELL LINE; GENE EXPRESSION REGULATION; GENETICS; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; PROTEIN TRANSPORT;

CATHEPSINS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; ENDOSOMES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROGEN-ION CONCENTRATION; LYMPHOCYTE ACTIVATION; LYSOSOMES; MELANOMA; PERFORIN; PROTEIN TRANSPORT; QB-SNARE PROTEINS; QC-SNARE PROTEINS;

EID: 84960172466     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10823     Document Type: Article

References (57)

1. Griffiths, G. M., Tsun, A. & Stinchcombe, J. C. The immunological synapse: a focal point for endocytosis and exocytosis. J. Cell Biol. 189, 397-406 (2010).
2. Huse, M., Quann, E. J. & Davis, M. M. Shouts, whispers and the kiss of death: directional secretion in T cells. Nat. Immunol. 9, 1105-1111 (2008).
3. Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1-10 (2013).
4. Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P. & Boon, T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat. Rev. Cancer 14, 135-146 (2014).
5. Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62-68 (2015).
6. Gajewski, T. F. et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 25, 268-276 (2013).
7. Kalos, M. & June, C. H. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39, 49-60 (2013).
8. Wimmers, F., Schreibelt, G., Skold, A. E., Figdor, C. G. & De Vries, I. J. Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets. Front. Immunol. 5, 165 (2014).
9. Aris, M. & Barrio, M. M. Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front. Immunol. 6, 46 (2015).
10. Stinchcombe, J. C., Bossi, G., Booth, S. & Griffiths, G. M. The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity 15, 751-761 (2001).
11. Law, R. H. P. et al. The structural basis for membrane binding and pore formation by lymphocyte perforin. Nature 468, 447-U277 (2010).
12. Faroudi, M., Zaru, R., Paulet, P., Muller, S. & Valitutti, S. Cutting edge: T lymphocyte activation by repeated immunological synapse formation and intermittent signaling. J. Immunol. 171, 1128-1132 (2003).
13. Bertrand, F. et al. An initial and rapid step of lytic granule secretion precedes microtubule organizing center polarization at the cytotoxic T lymphocyte/ target cell synapse. Proc. Natl Acad. Sci. USA 110, 6073-6078 (2013).
14. Lopez, J. A., Brennan, A. J., Whisstock, J. C., Voskoboinik, I. & Trapani, J. A. Protecting a serial killer: pathways for perforin trafficking and self-defence ensure sequential target cell death. Trends Immunol. 33, 406-412 (2012).
15. Baran, K. et al. The molecular basis for perforin oligomerization and transmembrane pore assembly. Immunity 30, 684-695 (2009).
16. Lopez, J. A. et al. Perforin forms transient pores on the target cell plasma membrane to facilitate rapid access of granzymes during killer cell attack. Blood 121, 2659-2668 (2013).
17. Thiery, J. et al. Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells. Nat. Immunol. 12, 770-U146 (2011).
18. de Saint Basile, G., Menasche, G. & Fischer, A. Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. Nat. Rev. Immunol. 10, 568-579 (2010).
19. Voskoboinik, I. & Trapani, J. A. Perforinopathy: a spectrum of human immune disease caused by defective perforin delivery or function. Front. Immunol. 4, 441 (2013).
20. Zhuang, L. et al. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod. Pathol. 20, 416-426 (2007).
21. Lickliter, J. D. et al. Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction. Br. J. Cancer. 96, 600-608 (2007).
22. Caramalho, I., Faroudi, M., Padovan, E., Muller, S. & Valitutti, S. Visualizing CTL/melanoma cell interactions: multiple hits must be delivered for tumour cell annihilation. J. Cell. Mol. Med. 13, 3834-3846 (2009).
23. Valitutti, S., Muller, S., Dessing, M. & Lanzavecchia, A. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J. Exp. Med. 183, 1917-1921 (1996).
24. Zimmerer, R. M. et al. Functional features of cancer stem cells in melanoma cell lines. Cancer Cell. Int. 13, 78 (2013).
25. Lopez, J. A. et al. Rapid and unidirectional perforin pore delivery at the cytotoxic immune synapse. J. Immunol. 191, 2328-2334 (2013).
26. Reddy, A., Caler, E. V. & Andrews, N. W. Plasma membrane repair is mediated by Ca(2+)-regulated exocytosis of lysosomes. Cell 106, 157-169 (2001).
27. Jimenez, A. J. et al. ESCRT machinery is required for plasma membrane repair. Science 343, 1247136 (2014).
28. Joulia, R. et al. Mast cells form antibody-dependent degranulatory synapse for dedicated secretion and defence. Nat. Commun. 6, 6174 (2015).
29. Korpetinou, A. et al. Serglycin: at the crossroad of inflammation and malignancy. Front. Oncol. 3, 327 (2014).
30. Meen, A. J. et al. Serglycin is a major proteoglycan in polarized human endothelial cells and is implicated in the secretion of the chemokine GRO alpha/CXCL1. J. Biol. Chem. 286, 2636-2647 (2011).
31. Balaji, K. N., Schaschke, N., Machleidt, W., Catalfamo, M. & Henkart, P. A. Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation. J. Exp. Med. 196, 493-503 (2002).
32. Baran, K. et al. Cytotoxic T lymphocytes from cathepsin B-deficient mice survive normally in vitro and in vivo after encountering and killing target cells. J. Biol. Chem. 281, 30485-30491 (2006).
33. Matarrese, P. et al. Cathepsin B inhibition interferes with metastatic potential of human melanoma: an in vitro and in vivo study. Mol. Cancer. 9, 207 (2010).
34. Rao, S. K., Huynh, C., Proux-Gillardeaux, V., Galli, T. & Andrews, N. W. Identification of SNAREs involved in synaptotagmin VII-regulated lysosomal exocytosis. J. Biol. Chem. 279, 20471-20479 (2004).
35. Soares, H. et al. Regulated vesicle fusion generates signaling nanoterritories that control T cell activation at the immunological synapse. J. Exp. Med. 210, 2415-2433 (2013).
36. Misinzo, G., Delputte, P. L. & Nauwynck, H. J. Inhibition of endosomelysosome system acidification enhances porcine circovirus 2 infection of porcine epithelial cells. J. Virol. 82, 1128-1135 (2008).
37. Valitutti, S., Muller, S., Salio, M. & Lanzavecchia, A. Degradation of T cell receptor (TCR)-CD3-xi complexes after antigenic stimulation. J. Exp. Med. 185, 1859-1864 (1997).
38. Sykulev, Y., Joo, M., Vturina, I., Tsomides, T. J. & Eisen, H. N. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 4, 565-571 (1996).
39. Purbhoo, M. A., Irvine, D. J., Huppa, J. B. & Davis, M. M. T cell killing does not require the formation of a stable mature immunological synapse. Nat. Immunol. 5, 524-530 (2004).
40. Pham, C. T. N. & Ley, T. J. Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc. Natl Acad. Sci. USA 96, 8627-8632 (1999).
41. D'Angelo, M. E. et al. Cathepsin H is an additional convertase of pro-granzyme B. J. Biol. Chem. 285, 20514-20519 (2010).
42. Yuseff, M. I. et al. Polarized secretion of lysosomes at the B cell synapse couples antigen extraction to processing and presentation. Immunity 35, 361-374 (2011).
43. Keefe, D. et al. Perforin triggers a plasma membrane-repair response that facilitates CTL induction of apoptosis. Immunity 23, 249-262 (2005).
44. Thiery, J. et al. Perforin activates clathrin-and dynamin-dependent endocytosis, which is required for plasma membrane repair and delivery of granzyme B for granzyme-mediated apoptosis. Blood 115, 1582-1593 (2010).
45. Reddy, A., Caler, E. & Andrews, N. W. Plasma membrane repair is mediated by Ca2+-regulated exocytosis of lysosomes. Mol. Biol. Cell 12, 266A-266A (2001).
46. Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570 (2011).
47. Lehmann, C., Zeis, M., Schmitz, N. & Uharek, L. Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells. Blood 96, 594-600 (2000).
48. Jazirehi, A. R., Nazarian, R., Torres-Collado, A. X. & Economou, J. S. Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor. Am. J. Clin. Exp. Immunol. 3, 43-56 (2014).
49. Jazirehi, A. R., Baritaki, S., Koya, R. C., Bonavida, B. & Economou, J. S. Molecular mechanism of MART-1+/A∗0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. Cancer Res. 71, 1406-1417 (2011).
50. Murakami, T. et al. Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J. Exp. Med. 198, 1337-1347 (2003).
51. Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793-800 (2002).
52. Taube, J. M. Emerging immunologic biomarkers: setting the (TNM-immune) stage. Clin. Cancer Res. 20, 2023-2025 (2014).
53. Ribas, A. Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin. Oncol. 37, 450-454 (2010).
54. Lindsay, C. R., Spiliopoulou, P. & Waterston, A. Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. Ther. Adv. Med. Oncol. 7, 107-121 (2015).
55. Frohlich, E. Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target. Cell Mol. Life Sci. 67, 3947-3960 (2010).
56. Vasconcelos, Z. et al. Individual human cytotoxic T lymphocytes exhibit intraclonal heterogeneity during sustained killing. Cell Rep. 11, 1474-1485 (2015).
57. Sanchez-Ruiz, Y., Valitutti, S. & Dupre, L. Stepwise maturation of lytic granules during differentiation and activation of human CD8+ T lymphocytes. PLoS ONE 6, e27057 (2011).